Physician profile
Daniel Baik
NPI 1851738819
$7,270.24
in general payments reported to CMS, 2019-2025
39 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.55 · 2020: $70.38 · 2021: $269 · 2022: $1,582 · 2023: $1,388 · 2024: $2,192 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,312 · Education: $25.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,311.89 |
| Education | $25.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,259.10 | 2022-2025 | Acquire, Dreamtome Rx 49, Active Cord |
| Abbvie INC. | $968.40 | 2020-2025 | Skyrizi, Rinvoq, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $529.05 | 2020-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.31 | 2020-2025 | Trulance, Xifaxan, Plenvu |
| Olympus America INC. | $392.94 | 2019-2025 | Single Use Electrosurgical Knife Kd-655, Evis Eus Endoscopic Ultrasound Center, Endoclot Phs |
| Fujifilm Healthcare Americas Corporation | $368.51 | 2024-2025 | Fujifilm |
| Madrigal Pharmaceuticals | $354.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $241.54 | 2024 | Endoflip |
| Janssen Biotech, INC. | $224.84 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Conmed Corporation | $175.00 | 2024 | Conmed Hemostasis, Conmed Biliary |
| Regeneron Healthcare Solutions, INC. | $172.59 | 2022-2025 | Dupixent |
| Celgene Corporation | $161.37 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $160.92 | 2023-2024 | Vemlidy |
| Lilly USA, LLC | $148.76 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $132.53 | 2024-2025 | Ibsrela |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $124.99 | 2022 | |
| Ambu INC. | $120.00 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $115.94 | 2023-2025 | Ocaliva |
| Endogastric Solutions, INC | $111.80 | 2023 | Esophyx |
| E.R. Squibb & Sons, L.L.C. | $103.82 | 2023 | |
| Qol Medical, LLC | $102.35 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $95.26 | 2021-2024 | Linzess |
| Genzyme Corporation | $93.44 | 2022-2025 | |
| Vivus LLC | $84.87 | 2025 | Qsymia, Pancreaze |
| Erbe USA INC | $70.00 | 2024 | |
| Celltrion USA INC. | $68.00 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $67.96 | 2021-2024 | Talicia |
| Capsovision, INC. | $54.73 | 2024-2025 | Capsocam Plus |
| Amgen INC. | $48.68 | 2025 | Uplizna |
| Phathom Pharmaceuticals, INC. | $46.49 | 2024-2025 | Voquezna |
| Pfizer INC. | $45.20 | 2022-2025 | |
| Exact Sciences Corporation | $35.93 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $29.60 | 2022 | |
| Braintree Laboratories, INC. | $28.83 | 2021-2024 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $27.57 | 2022 | |
| Seagen INC. | $18.35 | 2023 | Adcetris |
| Merck Sharp & Dohme LLC | $16.40 | 2023 | Dificid |
| Meridian Bioscience INC. | $15.93 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Baik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.